Personlig kost och läkemedel för kognition – Garcia-Ptacek forskargrupp

Garcia-Ptacek-gruppen syftar till att identifiera nya preventiva strategier och behandlingar för kognitiva sjukdomar och demens samt att definiera patientsubgrupper som har särskild nytta av specifika interventioner. Vi kombinerar läkemedelsrepositionering, genotypstyrt läkemedelsval och kostinterventioner med registerstudier, maskininlärning och biomarkörbaserad stratifiering för att utveckla individanpassade behandlingar vid Alzheimers sjukdom och andra neurodegenerativa sjukdomar.

En del av:

Publikationer

Alla gruppmedlemmars publikationer

Finansiering

Forskningsbidrag

  • Medication repurposing in dementia: selecting brain-friendly medications and establishing a new indication
    Centrum för Innovativ Medicin
    1 January 2026 - 31 December 2028
  • Medication repurposing to slow cognitive decline in Alzheimer's dementia
    ALF Medicin-Region Stockholm
    1 January 2026 - 31 December 2028
  • Neuroprotection with Repurposed Cardiovascular Drugs in Alzheimer's Disease
    Alzheimerfonden
    1 January 2025 - 31 December 2025
  • Nya innovativa vägar mot Alzheimers sjukdom: Vätskebiomarkörer och intracellulära behandlingar
    Private donation from Leif Lundblad Family and others
    1 October 2023 - 30 September 2026
  • Translationell identifiering av läkemedel för behandling av Alzheimersdemens
    Vetenskapsrådet
    1 January 2023 - 1 January 2026
  • Biomarkers and Intracellular treatments
    New Innovative Ways to Treat Alzheimer—Leif Lundblad and others-project
    1 January 2023 - 30 September 2025
  • Swedish Research Council
    1 January 2023 - 31 December 2026
    Dementia creates a great personal and societal burden and there are currently no treatments to stop memory loss.  Many patients with dementia take medications to treat other conditions, eg. high blood pressure and cholesterol. Some of these medications may have central effects on the pathophysiological processes leading to dementia.Medication repurposing is a cost and time-effective way to discover new treatments. Swedish registers are a unique tool to detect medication candidates for repurposing. The Swedish Dementia Registry (SveDem) has &gt
    100000 patients and ca. 144000 measures of cognition over time (measured with the Mini-Mental State Examination—MMSE), making it perfect to examine whether certain medications are associated with less cognitive decline in patients with dementia. Cholesterol and kidney function affect treatment and cognition and are available for 25000 patients. We propose a study combining traditional cohort studies and newer artificial intelligence (machine learning) techniques to detect medications associated with slower cognitive decline in patients from SveDem. We will test pre-specified hypotheses since we suspect specific medications are better candidates to prevent cognitive decline, but we will also let the machine learning algorithms explore the data to find associations that we do not suspect in advance. Finally, the candidate medications will be tested in animal and cellular models to determine the mechanisms of their effects.

Medarbetare och kontakt

Gruppledare

  • Sara Garcia Ptacek
    Biträdande Lektor | Docent

    Min forskning rör läkemedelsåteranvänding vid demens, med fokus på individualiserad prevention, upptäckt av nya behandlingar och biologisk patientstratifiering.

Alla medarbetare i gruppen

Besöksadress

Karolinska Institutet, Institutionen för Neurobiologi, Vårdvetenskap och Samhälle (NVS), Division of Clinical Geriatrics, Blickagången 16, 7e våning, Huddinge, Stockholm, 141 52, Sweden; Karolinska Institutet, NVS. Sektionen för klinisk geriatri/7e, Huddinge, Stockholm, 14183, Sweden

Postadress

Karolinska Institutet, NVS. Clinical Geriatrics, Huddinge, Stockholm, 141 83, Sweden